Healthcare
Shandong Weigao Group Medical Polymer Company Limited(SHWGF)
Live Price
Offline$0.43
+0.00% today
1Y Change
-42.11%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $13.36B
- Revenue Growth
- -0.3%
- EPS Growth
- -23.9%
- Dividend Yield
- 7.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shandong Weigao Group Medical Polymer Company Limited (SHWGF) is a Healthcare stock with a market cap of $13.36B and listed on OTC. The stock last traded around $0.43 and down 42.1% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of -23.9%, a dividend yield of 7.0%. What stands out right now is revenue -0.3%, EPS -23.9%, free cash flow -19.8% with operating margin 14.1% and ROIC 4.9%. The dividend matters to the case here, with a current yield around 7.0%. Valuation is more restrained than many high-expectation growth names at P/E 8.4 and price/sales 1.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SHWGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.3% vs +7.6% peer median
Operating Margin
Below sector median
+14.1% vs +19.4% peer median
P/E
Below sector median
8.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 27, 2026 with revenue ahead of estimates by 0.0%.
The operating picture looks softer than before
Revenue is at -0.3% and EPS is at -23.9%, with operating margin around 14.1%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 27, 2026 | +0.0% | -28.8% | -38.2% | -38.4% |
2025 Aug 27, 2025 | -14.7% | +0.0% | +0.0% | +0.0% |
2024 Dec 31, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHWGF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SHWGF Max Drawdown
-42.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHWGF and SPY.
Company Overview
Shandong Weigao Group Medical Polymer Company Limited
Other OTC
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.
- Leadership
- Rinan Cong
- IPO Date
- Jun 8, 2010
- Employees
- 12.7k
- Street Address
- Torch Hi-Tech Science Park
- Mailing
- Weihai, 264210
- Region
- Weihai, CN
- Reporting Currency
- USD
- Investor Line
- 86 63 1562 1999
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 8.4
- EV/EBITDA
- 3.7
- Price/Sales
- 1.0
- Price/Book
- 0.6
Growth
- Revenue
- -0.3%
- EPS
- -23.9%
- Free Cash Flow
- -19.8%
Profitability
- Gross Margin
- 46.6%
- Operating Margin
- 14.1%
- Net Margin
- 12.1%
- ROE
- 6.6%
- ROIC
- 4.9%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 3.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.